Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J E Grilley

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
The Journal of Biological Chemistry|December 16, 1998
A new remote subsite in ribonuclease AB M Fisher, J E Grilley, R T Raines
Bioconjugate Chemistry|May 23, 2000
Sulfur shuffle: modulating enzymatic activity by thiol-disulfide interchangeJ M Messmore, S K Holmgren, J E Grilley, et al.
British Journal of Cancer|January 20, 2018
Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancerR D Kim, S R Alberts, C Peña, et al.
Investigational New Drugs|July 25, 2016
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumorsJ E Grilley-Olson, P L Bedard, A Fasolo, et al.
ESMO Open|June 29, 2023
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinomaB C Cho, K Penkov, I Bondarenko, et al.
British Journal of Cancer|June 28, 2012
Different cellular p16(INK4a) localisation may signal different survival outcomes in head and neck cancerN Zhao, M-K Ang, X-Y Yin, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The Journal of Biological Chemistry|December 16, 1998
A new remote subsite in ribonuclease AB M Fisher, J E Grilley, R T Raines
Bioconjugate Chemistry|May 23, 2000
Sulfur shuffle: modulating enzymatic activity by thiol-disulfide interchangeJ M Messmore, S K Holmgren, J E Grilley, et al.
British Journal of Cancer|January 20, 2018
Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancerR D Kim, S R Alberts, C Peña, et al.
Investigational New Drugs|July 25, 2016
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumorsJ E Grilley-Olson, P L Bedard, A Fasolo, et al.
ESMO Open|June 29, 2023
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinomaB C Cho, K Penkov, I Bondarenko, et al.
British Journal of Cancer|June 28, 2012
Different cellular p16(INK4a) localisation may signal different survival outcomes in head and neck cancerN Zhao, M-K Ang, X-Y Yin, et al.
Pageof 1